Drrx stock fda approval

DRRX DURECT Corporation Stock Quote - FINVIZ.com DURECT Corporation Announces Outcome of FDA Advisory Committee Meeting for POSIMIR® PR Newswire Jan-16-20 02:38PM U.S. FDA panel split over approval of Durect's non-opioid painkiller Reuters DURECT Corporation (DRRX) Stock Falls On AdComm Vote ...

Jan 16, 2020 · An FDA advisory group voted 6-6 that DURECT (NASDAQ:DRRX) submitted enough efficacy and safety data to support approval of bupivacaine extended-release sol 3 Healthcare Stocks With Huge FDA Decisions in January ... Dec 30, 2019 · Coupling this with the stock’s 30% short interest, we like the opportunity for meaningful upside into this drug’s late January expected approval and launch,” the five-star analyst noted. FDA Panel Split On DURECT's Drug, Intellipharma Plunges ... Jan 16, 2020 · The FDA's Anesthetic and Analgesic Drug Products Advisory Committee has delivered a split verdict over whether the regulatory agency should … DURECT Corp. DRRX:NASDAQ - Valuable Stock Market News and ... "An approval of DURECT Corp.'s Posimir would be a significant upside driver for shares. . .from a stock perspective, we see favorable risk/reward. . .we see potential of about 50–100% upside on an approval (company has said it would outlicense Posimir if approved)."

"An approval of DURECT Corp.'s Posimir would be a significant upside driver for shares. . .from a stock perspective, we see favorable risk/reward. . .we see 

Stock quote and company snapshot for DURECT CORP (DRRX), including profile, stock chart, recent news and events, analyst opinions, and research reports. 20 Jan 2020 16 Jan 2020 The committee will discuss new drug application (NDA) 204803, bupivacaine extended-release solution for instillation, submitted by DURECT  DURECT Corporation Trading Halted Today; FDA Advisory ...

Potential risks and uncertainties include, but are not limited to, the risks that the FDA advisory committee meeting will be delayed, that the committee will vote against approval of POSIMIR or

Just did my DD into Posimir, the drug that should have the most signifigant news coming up the soonest for them. While i do love the product that they are trying to get approval for (post operative non-opioid pain releif, which would be huge in today's opiod crisis) they are just submitting a CRL to the most recent FDA review of their NDA. Here's Why Drug Developer DURECT Corporation Plunged Today ... DURECT Corp. (NASDAQ:DRRX) is down 9.2% at 12:45 p.m. EDT after the U.S. Food and Drug Administration's advisory committee voted 14 to 3 recommending the agency not approve Remoxy ER, an abuse-deterrent extended-release pain medication being developed by its partner Pain Therapeutics (NASDAQ: PTIE). Here's Why DURECT Jumped Higher Today | The Motley Fool Shares of DURECT (NASDAQ:DRRX) are up 8% at 11:54 a.m. EST, having increased as much as 12% today, as investors jump in ahead of a Food and Drug Administration advisory committee meeting to … DRRX DURECT Corporation Stock Quote - FINVIZ.com

Jul 22, 2019 · If the FDA approves this response, the company’s stock could benefit. The FDA has approved Indivior’s Perseris for the treatment of schizophrenia. Durect is eligible to receive single-digit

DRRX Stock Price | Durect Corp. Stock Quote ... - MarketWatch Durect Corp. DURECT Corp. is a biopharmaceutical company, which engages in the research, development, and manufacturing of pharmaceutical products. The company products include alzet and lactel. Its pipeline includes DUR-928, which focuses on lipid … FDA Calendar of Biotech Stock Catalysts • BioPharmCatalyst 151 rows · Biotech Stock Catalyst and FDA Calendar for your biotech stock investing. Use our tools on … Durect Corp. (DRRX) Stock Tumbles on FDA Opioid Analgesic ... Sep 26, 2016 · Durect Corp. (DRRX) Stock Tumbles on FDA Opioid Analgesic Drug Rejection Durect Corp.'s (DRRX) licensee Pain Therapeutics (PTIE) new drug application for an opioid analgesic was denied by the FDA U.S. FDA panel split over approval of Durect's non-opioid ...

Jan 17, 2020 · DRRX Stock Dives As Split Advisory Committee Hands Down Vote In a press release issued this morning, DURECT Corporation said that the United States Food and Drug Administration’s Anesthetic and Analgesic Drug Products Advisory Committee provided their view of POSIMIR in an Advisory Committee Meeting .

16 Jan 2020 16, 2020 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that NASDAQ has halted trading of the Company's common stock today. POSIMIR has not been approved by the FDA for marketing in the 

3 Healthcare Stocks With Huge FDA Decisions in January